Fifty pounds against thirty-three. That's the head-to-head math in one Zepbound commercial, and on Monday a federal judge declined to make Eli Lilly pull it. You're listening to GLP-1 Daily, and it's Tuesday, October 27. The Novo Nordisk versus Lilly ad fight is up first. Then South Korea puts obesity drugs up for an insurance review, and generic semaglutide maker Dr. Reddy's sets a November target to get its pens back on shelves.
Jonathan Stempel, reporting for Reuters:
Quraishi called Novo Nordisk's claim of irreparable harm "inadequate to warrant the extraordinary relief it seeks." The judge ruled after a two-day hearing in late August.
Back up to July. Novo sued, saying ads for Zepbound and Mounjaro broke false-advertising laws by putting higher doses of Lilly's drugs up against lower doses of Wegovy and Ozempic. One spot, with a written disclaimer, said Zepbound users lost fifty pounds on average and Wegovy users thirty-three. NDTV Profit's account lays out Novo's side. Those numbers came from a 2025 head-to-head trial, and in March the FDA approved a Wegovy dose triple the previous highest. Novo pointed to separate studies instead: forty-seven pounds on average for high-dose Wegovy, forty-eight for Zepbound. So two companies are arguing over which trials to set side by side, on TV, in one of the handful of countries that allows prescription-drug ads. Be precise about what was decided. This was a request for a preliminary injunction. Judge Zahid Quraishi found Novo hadn't shown lasting harm: its prescriptions stayed stable from April through July, and money damages could cover any real loss later. He called the case less than persuasive on a very preliminary record, but he did not rule on whether the ads are false. Novo says the litigation is ongoing. Lilly denies wrongdoing and says it's pleased. For patients, a weight-loss figure in an ad depends on the dose and the trial behind it. If one of these spots has you thinking about switching, ask your prescriber how the doses actually compare, and what your plan will cover.
Park Hong-yong, writing in the Seoul Economic Daily:
The managed benefit scheme brings non-reimbursed items at risk of overtreatment into the national health insurance system so that prices and treatment standards can be managed. It sets the patient co-payment rate at 95%, aiming to curb indiscriminate use of medical services while minimizing the burden on insurance finances. Whether obesity drugs will be included, which drugs would be covered, and the scope and timing of any application have not yet been decided.
This happened today, Korea time, at a parliamentary audit. Health Minister Jung Eun-kyeong said obesity drugs like Wegovy and Mounjaro would go into the review for that scheme after Representative Nam In-soon pressed her on coverage. Jung said drugmakers have already applied for reimbursement, and agreed to look at including patients without severe obesity. Read the co-pay again. Ninety-five percent, paid by the patient. This is less about the government paying for these drugs than about putting its pricing and prescribing rules on them. And the hearing showed why. Nam said nearly 97 percent of obesity-drug prescriptions override alerts from Korea's drug-review system, and 32.8 percent went ahead despite pregnancy warnings. Government data counted 70,018 prescriptions that proceeded past duplicate-ingredient alerts since October 2024. And the system won't flag Wegovy from one clinic plus Mounjaro from another, because they're different ingredients. Nam also cited 104 Korean patients treated for optic neuropathy after obesity-drug injections, while noting that no causal link has been established. That's the same eye question we covered on October 8. Korea's drug safety ministry is moving to designate these drugs as prone to misuse, and inspectors are visiting the 20 highest-prescribing clinics over suspected illegal in-house sales. What I'll be watching is whether managed pricing widens access or only polices it. A 95 percent co-pay sets a price; it doesn't make the drug affordable. One lesson travels. If more than one clinician prescribes for you, make sure each of them knows every medication you're on.
Drew Thornley, publisher of the trade site PPN:
Dr Reddy's Laboratories expects to relaunch generic semaglutide in Canada in November and has kept its guidance of 6 million to 7 million pens across 10 approved markets between November and March, with Canada taking most of the volume, Narasimham told Moneycontrol in an interview published Oct. 26.
Narasimham is the company's chief financial officer. Why it matters: in India, Reuters counted about 442,000 units of Dr. Reddy's generic semaglutide sold through September, nearly three times Sun Pharma. Then in July it halted its Obeda injection after finding an impurity in the active ingredient. Mind the gap between the interview and the paperwork. The company's October 23 filing says certain batches were out of specification because of an issue with the active ingredient, and it names no relaunch month. On that day's earnings call, CEO Erez Israeli said supplies could resume in November if validation succeeds. Canada also saw an August recall over an impurity and a labeling problem, which the company says was unrelated. Meanwhile in India, two new brands, Obeda Pro and Obeda Plus, showed up from a different contract manufacturer. Dr. Reddy's told Reuters they were planned before the disruption and shouldn't be read as replacements. Several distributors told Reuters they expect the original to be dropped. On Monday we heard South Africa's regulator say cheaper registered generics are part of the answer to the black market. That only works if the generic is reliably in stock and in spec. The U.S. isn't among the markets listed here, but if you fill semaglutide in Canada, ask your pharmacist which product you're getting before your next refill.
If GLP-1 Daily just saved you from reading a twenty-five-page court decision yourself, leave us a rating and a line of review in your podcast app. It's how other patients find the show.
Reuters, the Seoul Economic Daily and PPN are all in the episode notes, and anything here that fits your situation belongs in a conversation with your own prescriber. We're back tomorrow, Wednesday. GLP-1 Daily is a Lantern Podcast.